Fractyl Health, Inc. (NASDAQ:GUTS) Short Interest Update

Key Points

• Fractyl Health, Inc. experienced a 33.5% decrease in short interest in September, dropping from 2,540,000 shares to 1,690,000 shares, which is about 4.6% of its total shares.
• Recent hedge fund activity shows that several firms, including Catalyst Funds Management and Osaic Holdings Inc., have acquired new stakes in Fractyl Health, indicating growing interest in the stock.
• Fractyl Health reported an EPS of (0.53) for the last quarter, missing estimates, while analysts expect the company to post a -1.61 EPS for the current fiscal year.

Fractyl Health, Inc. (NASDAQ:GUTS - Get Free Report) was the target of a significant decrease in short interest in the month of September. As of September 15th, there was short interest totaling 1,690,000 shares, a decrease of 33.5% from the August 31st total of 2,540,000 shares. Currently, 4.6% of the shares of the stock are short sold. Based on an average daily volume of 858,700 shares, the days-to-cover ratio is presently 2.0 days. Based on an average daily volume of 858,700 shares, the days-to-cover ratio is presently 2.0 days. Currently, 4.6% of the shares of the stock are short sold.

Hedge Funds Weigh In On Fractyl Health

A number of hedge funds have recently modified their holdings of the stock. Catalyst Funds Management Pty Ltd purchased a new stake in shares of Fractyl Health during the second quarter worth $26,000. Jane Street Group LLC acquired a new position in Fractyl Health in the 2nd quarter worth about $31,000. Chicago Partners Investment Group LLC acquired a new position in Fractyl Health in the 1st quarter worth about $37,000. HighTower Advisors LLC raised its stake in shares of Fractyl Health by 57.9% during the 1st quarter. HighTower Advisors LLC now owns 40,921 shares of the company's stock worth $49,000 after purchasing an additional 15,000 shares in the last quarter. Finally, Osaic Holdings Inc. lifted its holdings in shares of Fractyl Health by 460.3% during the 2nd quarter. Osaic Holdings Inc. now owns 59,645 shares of the company's stock valued at $97,000 after buying an additional 49,000 shares during the last quarter.

Fractyl Health Price Performance

Shares of GUTS opened at $1.55 on Monday. The business's 50-day moving average is $1.17 and its 200-day moving average is $1.44. The company has a debt-to-equity ratio of 4.61, a current ratio of 1.22 and a quick ratio of 1.22. The company has a market capitalization of $77.95 million, a price-to-earnings ratio of -0.75 and a beta of 2.27. Fractyl Health has a fifty-two week low of $0.83 and a fifty-two week high of $3.48.

Fractyl Health (NASDAQ:GUTS - Get Free Report) last announced its quarterly earnings data on Tuesday, August 12th. The company reported ($0.53) EPS for the quarter, missing analysts' consensus estimates of ($0.37) by ($0.16). Equities research analysts expect that Fractyl Health will post -1.61 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of research firms have commented on GUTS. Canaccord Genuity Group dropped their price target on shares of Fractyl Health from $12.00 to $6.00 and set a "buy" rating on the stock in a research report on Thursday, August 14th. LADENBURG THALM/SH SH assumed coverage on Fractyl Health in a report on Thursday, August 28th. They set a "buy" rating and a $3.60 target price on the stock. Weiss Ratings restated a "sell (e+)" rating on shares of Fractyl Health in a research report on Saturday, September 27th. Finally, HC Wainwright lowered their price target on Fractyl Health from $9.00 to $8.00 and set a "buy" rating on the stock in a research report on Friday, September 26th. Four investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and a consensus target price of $6.90.

About Fractyl Health

Fractyl Health, Inc, a metabolic therapeutics company, develops therapies for the treatment of type 2 diabetes (T2D) and obesity. The company develops Revita DMR System (Revita), an outpatient procedural therapy designed to durably modify duodenal dysfunction, a pathologic consequence of a high fat and high sugar diet, which can initiate T2D and obesity in humans.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.